1) Although elevated homocysteine levels is not common among people living within Benin city and its environs, a larger scale research is needed to enhance our understanding of the effect of hyperhomocysteinaemia as a predictor of poor outcome.
This study will serve as basis for further research in this field, possibly with larger Multi-Centre studies.
2) There should be more enlightenment campaigns on the awareness of strokes and its risk factors as well as the importance of adherence to antihypertension medications and healthy life style modifications.
REFERENCES
1. Danesi M.A, Oyenola Y.A, Ontiri A.C. Risk factors associated with cerebrovascular accidents in Nigerians (A case-control study). E Afr Med J 1983; 60: 190-195.
2. Nyame P.K, Bonsu-Bruce N, Amoah A.G, Adjei S, Nyarko E, Amuah E.A. Current trends in the incidence of cerebrovascular accidents in Accra. W Afr Med J 1994;
13:183-186.
3. Ogun S.A, Odusote K.A. Effectiveness of high dose dexamethasone in the treatment of Acute stroke. W Afr Med J 2001; 20:1-4.
4. Acheampong JA. Stroke: Risk factors and factors predicting survival. Ghana Med J 2001; 35:148 -149.
5. Imam I. The profile of stroke in Nigeria’s federal capital territory. Tropical Doctor 2002; 32:209-211.
6. Walker R.W, Rolfe M, Kelly P.J, Melville O.G, Oliver JFW. Mortality and recovery after stroke in the Gambia. Stroke 2003; 34:1604-1609.
7. Wiredu E.K, Nyame P.K. Stroke mortality in Accra: A study of risk factors. Ghana Med J 2001; 35: 151-161.
8. Hankey G.J, Eikelboom J.W. Homocysteine and stroke. Current Opinion in Neurology 2001; 14:95-102.
9. Welch G.N, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;
338:1042-50.
10. Hankey G.J, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-413.
11. Kelly PJ, Rosand J, Plomaritoglou A, Chang Y, Kistler JP, Furie K. Mild-moderate hyperhomocysteinaemia and risk of stroke, result of a meta- analysis. Stroke 2000;
32:366.
12. Li Z, Li S, Hongye Z, Yuhua L, Daowen W.l. Elevated plasma homocysteine was associated with Hemorrhagic and ischemic stroke, but methylene tetra hydrofolate reductase gene C677 polymorphism was a risk factor for thrombotic stroke. A multi centre case-control study. Stroke2003; 34:2085-2090
13. Delport R, Ubbink JB, Vermaak WJ, Rossouw H,Becker PJ, Joubert J. Hyper homocysteinemia in black patients with cerebral thrombosis. QJM (England) 1997; 90:
635-9.
14. Fallon UB, Elwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD.
Homocysteine and ischemic stroke in men: the caerphily study. J Epidemiol Community Health 2001; 55:91-96.
15. El Kossi MMH, Zakhary MM. Oxidative stress in the context of acute cerebrovascular Stroke. Stroke2000; 31:1889-1892.
16. Glew, R.H, Okolie H, Crossey M, Suberu O, Trujillo M, Pereyra M, et al. Serum lipid profiles and homocysteine levels in adults with stroke or myocardial infarction in the town of Gombe in northern Nigeria. J Health Popl Nutr. 2004; 22:341-7.
17. Hankey GJ. Is Homocysteine a causal and treatable risk factor for vascular diseases of the brain? Annals of Neurology 2002; 51:279-281.
18. Meiklejohn D.J, Vickers M.A, Dijkhuisen R, Greave M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32:57–62.
19. Lindgren A, Brattstrom L, Norrving B, Hultberg B, .Andersson A, Johansson B.B et al.
Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;
26:795–800.
20. Ribo M, Montaner J, Monasterio J. Role of homocysteine in the acute phase of stroke, Neurologia 2004; 19:10–14.
21. Pniewski J, Chodakowska-Zebrowska M, Wozniak R, Stepien K, Stafiej A. Plasma homocysteine level and the course of ischemic stroke, Acta Neuro biologiae Experimentalis 2003; 63:127–130, 2003.
22. Hackam D.G, Peterson J.C, Spence D.J. What level of plasma homocysteine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocysteine levels above and below 14μmol/L. Am J Hypertens 2000; 13:105-110.
23. Giles WH, Kittner SJ, Croft JB, Woznizk MA,Wityk RJ. Distribution and correlates of elevated total homocysteine: the stroke prevention in young women study. Ann Epidemiol 1999; 9:307-313.
24. Amouzou E.K, Chabi N.W, Adjalla C.E, Rodriguez-Gueant R.M, Feillet F, Villaume C, et al. High prevalence of hyperhomocysteinemia related to folate deficiency and the 677C-T mutation of the gene encoding methylene tetrahydrofolate reductace in coastal West Africa. Am J Clin Nutr.2004; 79:619-24.
25. Okubadejo N.U, Oladipo O.O, Adeyomoye A.A, Awosanya G.O, Danesi M.A.
Exploratory study of plasma total homocysteine and its relationship to short term outcome in acute ischemic stroke in Nigerians. BMC Neurol. 2008; 12: 8-26.
26. WHO MONICA Project Investigators. The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease). J Clin Epidemiol 2004; 41, 105-114. 1988.
27. Sacco RL, Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, et al Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009; 40:2276–
2293.
28 Cole W. A Physico-Medical Essay Concerning the Late Frequency of Apoplexies Together With a General Method of Their Prevention and Cure: In a Letter to a Physician. Oxford, United Kingdom; The Theater; 1869. Reprinted by: New York, NY: Classics of Neurology & Neurosurgery Library; 1995
29. Fisher CM. Intermittent cerebral ischemia. In: Wright IS, Millikan CH, eds. Cerebral Vascular Diseases. New York, NY: Grune & Stratton; 1958:81–97.
30. Mohr JP. Historical perspective. Neurology. 2004;62: S3–S6.
31. Committee on Cerebrovascular diseases. A classification and outline of cerebrovascular diseases, II. Stroke. 1975; 6:564–616.
32. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL et al. Transient ischemic attack: proposal for a new definition. N Engl J Med. 2002; 347:1713–1716.
33. Centers for Disease Control and Prevention Web site. Classification of Diseases, Functioning, and Disability. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). http://www.cdc.gov/nchs/icd/icd10cm.htm#
10update. Accessed June 20, 2017.
34 Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A et al. AHA/ASA Expert Consensus Document: An Updated Definition of Stroke for the 21st Century A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2013; 44:2064-2089.
35. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge: Harvard University Press; 1996.
36. World Health Organization. The World Health Report: 2002: Reducing risks, promoting healthy life. 2002. World Health Organization.
37. Connor MD, Walker R, Modi G, Warlow CP. Burden of stroke in black populations in sub-Saharan Africa. Lancet Neurol. 2007;6:269-78.
38. Danesi M, Okubadejo N, Ojini F: Prevalence of Stroke in an Urban, Mixed Income community in Lagos, Nigeria. Neuroepidemiology. 2007; 28: 216–223.
39. Feign VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383:245-255
40. Osuntokun BO, Adeuja AO, Schoenberg BS, Bademosi O, Nottidge VA, Olumide AO et al. Neurological disorders in Nigerian Africans: a community-based study. Acta Neurol Scand 1987; 75: 13–21.
41 Osuntokun B.O, Bademosi O, Akinkugbe O.O, Oyediran A.B, Carlisle R. Incidence of stroke in an African city: results from the stroke registry at Ibadan, Nigeria, 1973– 1975.
Stroke 1979; 10: 205–207.
42. Nwosu C.M, Enwereji K.O, Nwani P.O, Asomugha A.L, Ogunniyi A. Epidemiology of stroke in a rural community in South eastern Nigeria. Vasc Health Risk Manag. 2014;
10: 375–388.
43. Sanya E.O, Desalu O.O, Adepoju F, Aderigbigbe A. Prevalence of stroke in three semi-urban communities in middle-belt region of Nigeria: a door to door survey. The Pan African Medical Journal. 2015; 20:33
44. Onwuchekwa A.C, Tobin-west C, Babatunde S. Prevalence and Risk Factors for Stroke in an Adult Population in a Rural Community in the Niger Delta, South-South Nigeria.
Journal of Stroke and Cerebrovascular Diseases.2013; 505-510
45. Ogun S.A, Ojini F.I, Ogungbo B, Kolapo K.O, Danesi M.A. Stroke in South west Nigeria, a 10-year review. Stroke 2005; 36:1120-1122.
46 Adeloye D. An estimate of the incidence and prevalence of stroke in Africa: a systematic review and meta-analysis. PLoS One 2014; 9(6): e100724
47 Owolabi MO, Akarolo-Anthony S, Akinyemi R, Arnett D, Gebregziabher M, Jenkins C. The burden of stroke in Africa: a glance at the present and a glimpse into the future.
Cardiovasc J Afr 2015;S27-S38.
48. Yin NS, Benavides S, Starkman S, Liebeskind DS, Saver JA, Salamon N et al Autopsy findings after intracranial thrombectomy for acute ischemic stroke: a clinicopathologic study of 5 patients. Stroke 2010; 41:938–947.
49. Petito CK. The neuropathology of focal brain ischemia. In: Kalimo H. ed. Pathology &
Genetics: Cerebrovascular Diseases. Basel, Switzerland: ISN Neuropath Press;
2005:215–221.
50. Vinters HV, Farrell MA, Mischel PS, Anders KH. Anoxic-ischemic change and cerebrovascular disease. In: Diagnostic Neuropathology. New York, NY: Marcel Dekker; 1998: 51–146.
51. Hazrati LN, Bergeron C, Butany J. Neuropathology of cerebrovascular diseases. Semin Diagn Pathol. 2009; 26:103–115.
52. Vinters HV. Cerebrovascular disease: practical issues in surgical and autopsy pathology.
In: Love S, ed. Neuropathology. A Guide for Practicing Pathologists. Berlin-Heidelberg, Germany: Springer; 2001:51–99.
53. Busl KM, Greer DM. Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms. Neuro Rehabilitation. 2010; 26:5–13.
54. Wirenfeldt M, Babcock AA, Vinters HV. Microglia: insights into immune system structure, function, and reactivity in the central nervous system. Histol Histopathol.
2011; 26:519–530.
55. Clare H.R. Cerebral microinfarcts associated with severe cerebral beta amyloangiopathy. Brain Pathol. 2010; 20:459–467.
56. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ. Neuropathologic substrates of ischemic vascular dementia. J Neuro pathol Exp Neurol. 2000; 59:931–
945.
57. Thanvi B, Robinson T: Sporadic cerebral amyloid angiopathy—an important cause of cerebral hemorrhage in older people. Age and Ageing 2006; 35: 565–571.
58 Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009; 373:
1632–1644.
59 Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF. Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood Flow Metab. 2003; 23: 629–652.
60 Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage.
Lancet Neurol. 2006; 5: 53–63
61. Truelsen T, Bonita R: The worldwide burden of stroke: current status and future projections. Handb Clin Neurol. 2009; 92: 327-36.
62. Feigin VL, Rinkel GJ, Lawes CM: Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005; 36: 2773–80.
63. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K et al. A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg. Psychiatry 1988; 51:1373-80.
64. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke 1988; 19:1497-500.
65. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.
Stroke 1994; 25: 333-337.
66. Appelros P, Nydevik I, Viitanen M. Poor Outcome After First-Ever Stroke.
Predictors for Death, Dependency, and Recurrent Stroke Within the First Year. Stroke 2003; 34:.122-128
67. Hu HH, Sheng WY, Chu FL, Lan CF, Chiang BN, Lo YK. - Incidence of Stroke in Taiwan. Stroke 1992; 23:1237-41.
68. Suzuki K, Kutsuzawa T, Takita K, Ito M, Sakamoto T, Hirayama A et al.
Clinicoepidemiologic study of stroke in Akita, Japan. Stroke 1987; 18:402-406.
69. Kay R, Woo J, Kreel L, Wong HY, Teoh R, Nicholls MG. Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry. Neurology 1992; 42:98587.
70. Asian Acute Stroke Advisory Panel. Stroke epidemiological data of nine Asian countries. J Med Assoc Thai 2000; 83: 1-7.
71. Shi FL, Hart RG, Sherman DG, Tegeler CH. Stroke in the People's Republic of China.
Stroke 1989; 20:1581-85.
72. Yaqub BA, Shamena AR, Kolawole TM, Patel PJ. - Cerebrovascular disease in Saudi Arabia. Stroke 1991; 22:1173-6.
73. Al-Rajeh S, Larbi EB, Bademosi O, Awada A, Yousef A, al-Freihi H et al. Stroke register: experience from the eastern province of Saudi Arabia. Cerebrovascular Diseases 1998; 8:86-89.
74. Awada A, Al Rajeh S. The Saudi Stroke Data Bank. Analysis of the first 1000 cases.
Acta Neurol Scand 1999; 100:265-69.
75. Saposnik G, Caplan LR, Gonzalez LA, Baird A, Dashe J, LuraschiA et al. Differences in stroke subtypes among natives and Caucasians in Boston and Buenos Aires. Stroke 2000; 31:2385-89.
76. Matenga J, Kitai I, Levy L. Strokes among black people in Harare, Zimbabwe: results of computed tomography and associated risk factors. BMJ 1986; 292:1649-51.1986.
77. Joubert J. The MEDUNSA Stroke Data Bank. An analysis of 304 patients seen between 1986 and 1987. S Afr Med J 1991; 80:567-70.
78. Connor M, Warlow, C. Stroke in Sub-Saharan Africa: a systematic review. Lancet neurol 2007; 6:269-78.
79. Rosman, K. D. The epidemiology of stroke in an urban black population. Stroke 1986;
17:667-669.
80. Eastern Stroke and Coronary Heart Disease Collaborative Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352, 1801-1807.
81. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke.
13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346, 16471653.
82. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
83. Medical Research Council Working Party MRC trial of treatment of mild hypertension:
principal results. BMJ 1985;291: 97–104.
84. Thomson R. Evidence based implementation of complex interventions. BMJ 2009; 339:
b3124.
85. Hankey GJ. Smoking and risk of stroke. JCR 1999; 6:207–11.
86. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995; 274: 155–60.
87. Reynolds K, Lewis B. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289: 579–88
88. O’Donnel JMl, Xavie Dr, Liu L. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010:
376; 112–23
89. Yusuf S, Hawken S, Ôunpuu S, on behalf of the INTERHEART Study Investigators.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: 937–
52.
90. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality:
estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009; 8: 345–
54.
91. Truelsen T, Mahonen M, Tolonen H, Asplund K, Bonita R, Vanuzzo D. Trends in stroke and coronary heart disease in theWHO MONICA Project. Stroke 2003; 34: 1346–52.
92 Adams H.P, Davis P.H, Leira E.C, Chang K.C, Bendixen B.H, Clarke W.R, et al.
Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 1126.
93 Cote R, Hachinski V.C, Shurvell B.L, Norris J.W, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke 1986; 17:731-7.
94 Cote R, Battista R.N, Wolfson C, Boucher J, Adam J, Hachinski V. The Canadian neurological scale validation and reliability assessment. Neurology 1989; 39:638.
95 Duncan P.W, Lai S.M, Van Culin V, Huang L, Clausen D, Wallace D. Development of a comprehensive assessment toolbox for stroke. Clinics in geriatric medicine 1999;
15:885-915.
96 Nilanont Y, Komoltri C, Saposnik G, Côté R, Di Legge S, Jin Y, et al. The Canadian Neurological Scale and the NIHSS: development and validation of a simple conversion model. Cerebrovascular diseases 2010; 30:120-6.
97. Martin-Schild S, Albright KC, Tanksley J. Zero in the NIHSS does not equal the absence of stroke. Ann Emerg Med. 2011;57: 42–45.
98 Sato S, Toyoda K, Uehara T. Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes. Neurology. 2008;70:2371–2377
99 Woo D, Broderick J.P, Kothari R.U. Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? Stroke. 1999;30:2355–2359.
100 Bushnell C. D. Johnston C.C, Goldstein B.L. Retrospective Assessment of Initial Stroke Severity Comparison of the NIH Stroke Scale and the Canadian Neurological Scale.
Stroke 2001;32:656-660
101 Quinn TJ, Dawson J, Walters M. Dr John Rankin; his life, legacy and the 50th anniversary of the Rankin Stroke Scale. Scot Med J. 2008;53:44–47.
102 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry.
1991;54:1044–1054.
103 Quinn TJ, McArthur K, Dawson J, Walters MR, Lees KR. Reliability of structured modified Rankin Scale assessment. Stroke. 2010;41:602–603.
104 Sternbach GL. The Glasgow Coma Score. J Emerg Med. 2000 Jul;19:67-71.
105. Du Vigneaud V, Ressler C, Rachele JR. The biological synthesis of "labile methyl groups." Science 1950; 112:267-271.
106. Carson N.J, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962; 37:505-513.
107. Gerritsen T, Vaughn JG, Weisman HA. The identification of homocysteine in the urine.
Biochem Biophys Res Commun 1962; 9:493.
108. Gerritsen T, Waisman HA. Homocystinuria, an error in the metabolism of methionine.
Pediatrics 1964; 33:413-420.
109. Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect.
Science 1964; 143: 1443-1445.
110. Gibson J.B, Carson N.J, Neill DW. Pathological findings in homocystinuria. J Clin Pathol. 1964; 17:427-437.
111. Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria. JAMA 1965;
193:711-719.
112. White HH, Rowland LP, Araki S, Thompson HL, Cowen D. Homocystinuria. Arch Neurol 1965; 13:455-470.
113. McCully KS, Wilson RB. Homocystinuria theory of arteriosclerosis. Atherosclerosis 1975; 22:215-227.
114. McCully KS. Homocysteine theory of arteriosclerosis: development and current status.
Atherosclerosis Rev 1983; 11:157-246.
115. Wilcken DL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57:1079-1082.
116. Boers GHJ, Smals AH, Drayer JM, Trijbels FJM, Leermakers AI, Kloppenberg,PW.
Pyridoxine treatment does not prevent homocystinemia after methionine loading in adult homocystinuria patients. Metab Clin Exp 1983; 32:390-397.
117. Drell W, Welch AD. Azaribine-homocystinemia-thrombosis in historical perspectives.
Pharmacol Ther 1989; 41: 195-206.
118. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease and the carrier state for homocystinuria. Metabolism 1983; 32:363-370.
119. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984; 15: 1012-1016.
120. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-421.
121. Gupta VI, Wilcken DL. The detection of cysteine-homocysteine mixed disulphide in plasma of normal fasting man. Eur J Clin Invest 1978; 8:205-207.
122. Wilcken DEL, Gupta VI. Cysteine-homocysteine mixed disulphide: differing plasma concentrations in normal men and women. Clin Sci 1979; 57:211-215
123. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72:1971 1976.
124. Kang S.S, Wong PWK, Becker N. Protein-bound homocysteine in normal subjects and in patients with homocystinuria. Pediatric Res 1979; 13: 1141-1143.
125. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31:624-628.
126. Kang S-S, Wong PWK, Cook HY, Norusis M, Messer IV. Protein-bound
homocysteine. A possible risk factor for coronary artery disease. J Clin Invest 1986;
77:1482-1486.
127. Israelsson B, Brattstrom LE, Hultberg BJ. Homocysteine and myocardial infarction.
Atherosclerosis 1988; 71:227-234.
128. Malinow MR, Kang SS, Taylor LM. Prevalence of hyperhomocysteinaemia in patients with peripheral arterial occlusive disease. Circ Res 1989; 19: 1180-1188.
129. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydrylcontaining amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-146.
130. Brattstrom L, Israelsson B, Norrving B. Impaired homocysteine metabolism in earlyonset cerebral and peripheral occlusive arterial disease-effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51-60.
131. Malinow MR. Hyperhomocysteinaemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81:2004-2006.
132. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Olsson AG.
Hyperhomocysteinaemia: an independent risk factor for intermittent claudication. J Internal Med. 1992; 231:273-279
133. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422:43-52.
134. Wiley VC, Dudman NPB, Wilcken DEL Interrelations between plasma free and protein-bound homocysteine and cysteine in homocystinuria. Metabolism 1988;37:
191-195.
135. Smolin LA, Benevenga NJ. The use of cysteine in the removal of protein-bound homocysteine. Am I Clin Nutr 1984; 39:730-737.
136. Finkelstein JD, Martin n, Harris BJ. Methionine metabolism in mammals. The methionine-sparing effect of cystine. J BioI Chem 1988;263: 11750-11754.
137. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. American Journal of Clinical Nutrition 1994; 59:1033–1039.
138. Stehouwer C, van Guldener C. Homocysteine-lowering treatment: an overview. Expert Opinion on Pharmacotherapy 2001; 2: 1449–1460.
139. Lonn E, Yusuf S, Arnold M.J, Sheridan P, Pogue J, Micks M et al. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease N Engl J Med 2006;
354:1567–77
140. Kwiterovich P.O. The John Hopkins complete guide for preventing and reversing Heart Disease 1993; 163-176
141. Pritikin N, McGrady M. The Pritikin Program for Diet and Exercise (New York:
Grosset & Dunlap 1979), pp. 79-105
142. Ornish D, Brown S.E, Scherwitz L.W, billings J.h. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336:129-133
143. Naruszewicz M, Mirkieicz E, Olszewski A.J, McCully K.S. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutrition, Metabolism and Cardiovascular Diseases 1994; 4:70-77
144. McCully K.S. The homocysteine revolution (Illinois: keats publishing, 1999), pp 25-105
145. McCully K.S. Homocysteine and vascular disease. Nature Medicine 1996; 2:386-389 146. Hamfelt. A. Age variation of vitamin B6 metabolism in man. Clinica Chemica Acta
1964; 10:48-54
147. Jacob S, Jacques. P. F, Wilson. W.F. Vitamin status and intake as primary determinants of homocystinemia in the elderly population. JAMA 1993; 270:26932698
148. Ubblink J.B, Haywardn-Vermmaak W.J, Bennett J.M. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klinische /wochenschrift 1991; 69:527-534
149. Ubblink J. B, Haywardn-Vermmaak W.J, Delport R. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. AJCN 1995; 62:802-808
150. Calabrese E.J. Environmental validation of the homocysteine theory of
arteriosclerosis. Medical Hypotheses 1984; 15:361-367
151. Friedman J A , Dwyer J T. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutrition Reviews 1995; 53:197-201 152. Nabili S T. What is considered as high levels of Homocysteine? (Last review, August
2008). http://www.medicinenet.com/homocysteine/page2.htm. Accessed on 13th December 2013
153. Akpalu A.K, Nyame P.K. Plasma Homocysteine as a Risk Factor for Strokes in Ghanaian Adults. Ghana Med J 2009; 43:157–163.
154. Jekel JF, Elmore JG, Katz DL. Sample size, randomization and probability theory.
Epidemiology, Biostatistics and Preventive Medicine. Philadelphia: Saunders; 1996;
159-171
155. Brown RD, Whisnant JP, Sicks RD, O’Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke.
1996; 27:373-380.
156. Wolf PA, D’agostino RB, O’neal MA, Sytkowski P, Kase CS. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke 1992; 23:1551-1555.
157. Miettinen H, Haffner S, Lehto S, Ronnemaa T, Pyorala K. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and noninsulin-dependent diabetic subjects. Stroke 1996; 27:2033-2039.
158. Madison J, Spies C, Schatz J. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. Arch Intern Med 2006;
166:884-89.
159. VanderJagt DJ, Spelman K, Ambe J, Datta P, Blackwell W, Glew R.H et al. Folate and vitamin B12 status of adolescent girls in northern Nigeria. Natl Med Assoc. 2000;
92:334-40.
160. Happaniemi E, Helenius J, Soinne L, Syrjala M, Kaste M, Tatlisumak T. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol. 2007;14:12–17
161. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke. 2003; 34:1258-61.
162. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, Arzenton E et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci. 2005 Dec; 26:310-18.
163. Yoldas T, Gonen M, Godekmerdan A, Ilhan F, Bayram E. The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke. Mediators Inflamm. 2007; 10:1155.
164. Mizrahi EH, Fleissig Y, Arad M, Adunsky A. Plasma homocysteine level and functional outcome of patients with Ischemic stroke. Arch Phys Med Rehabil. 2005;
86:60–63.
165. Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem. 2001 Mar; 34:97-101.
166. Owolabi M.O, Arulogun O , Melikam S, Adeoye A.M, Akarolo-Anthony S , Akinyemi R, et al. The burden of stroke in Africa: a glance at the present and a glimpse into the future. Cardiovasc J Afr. 2015; 26: 27- 38.
167. Sacco RL, Wolf PA, Gorelick PB. Risk factors and their management for stroke prevention: outlook for 1999 and beyond. Neurology. 1999; 53:15–S24
168. Ralph L, Emelia J, Benjamin J, Broderick M, Dyken J. Donald E et al. Risk Factors of stroke. Stroke. 1997;28:1507-1517
169. National Center for Health Statistics. Blood Pressure Levels in Persons 18-74 Years of Age in 1976-1980, and Trends in Blood Pressure From 1960 to 1980 in the United States. Vital and Health Statistics, series 11. Washington, DC: US Government Printing Office; 1986. DHHS publication 86-1684.
170. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence: the Honolulu Heart Program. Stroke.
1994;25:951-957.
171. Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am J Kidney Dis. 2009; 53:41
172. Kumai Y, Kamouchi M, Hata. Proteinuria and clinical outcomes after ischemic stroke.
Neurology 2012; 78:1909-15
173 Hyung-Min K, Yong-Seok L, Hee-Joon B, Dong-Wha K. Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke. Stroke 2014; 45:871-873